Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.

Cancer research - 16 Jan 2026

Chen Pan-Yu, Bollag Gideon

Abstract excerpt

Targeted inhibition of mutant BRAF has transformed the management of BRAF-V600-mutant melanoma and other malignancies, with multiple ATP-competitive kinase inhibitors now approved for clinical use. Despite their clinical success, these agents are limited by intrinsic and acquired resistance, paradoxical activation of the MAPK pathway, and dose-limiting toxicities. The development of BRAF-V600X...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to BRAF gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Melanoma

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 41540849
DOI: 10.1158/0008-5472.CAN-25-4381

Genes

BRAF
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.PMID 41540849Read ↗

CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.Semantic proximity Read ↗

Mutant-selective Degradation by BRAF-targeting PROTACsSemantic proximity Read ↗

Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation.Semantic proximity Read ↗

Mutant-selective degradation by BRAF-targeting PROTACs.Semantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

Functional characterization of a PROTAC directed against BRAF mutant V600E.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Biological challenges of BRAF inhibitor therapy.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

A new BRAF inhibitor breaks resistance barriers.Semantic proximity Read ↗

RAF inhibitors that evade paradoxical MAPK pathway activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.